Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

Health Behaviors Predict Higher Interleukin-6 Levels among Patients Newly Diagnosed with Head and Neck Squamous Cell Carcinoma

(2013) S. A. Duffy et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

(2013) T-H Lin et al.   Cell Death & Disease

The Proinflammatory Cytokine, IL-6, and its Interference with bFGF Signaling and PSMA in Prostate Cancer Cells

(2012) Awatef Ben Jemaa et al.   INFLAMMATION

Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer

(2012) Wenwei Hao et al.   MEDICAL ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

(2012) Y Li et al.   ONCOGENE

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

(2011) M. S. Anglesio et al.   CLINICAL CANCER RESEARCH

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

MDV3100 has antitumor activity in castration-resistant disease

(2010) Sarah Payton   Nature Reviews Urology

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Inflammation and Cancer: IL-6 and STAT3 Complete the Link

(2009) Jacqueline Bromberg et al.   CANCER CELL

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3)

(2009) Laure Dossus et al.   CARCINOGENESIS

Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells

(2009) J. Y. Chun et al.   CLINICAL CANCER RESEARCH

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

(2009) S. Feng et al.   MOLECULAR CANCER THERAPEUTICS

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Stat3 Promotes Metastatic Progression of Prostate Cancer

(2008) Junaid Abdulghani et al.   AMERICAN JOURNAL OF PATHOLOGY

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

(2008) Sergei Grivennikov et al.   CANCER CELL